Skip to main content

Drug Interactions between fluvoxamine and pentoxifylline

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

pentoxifylline fluvoxaMINE

Applies to: pentoxifylline and fluvoxamine

MONITOR: Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of pentoxifylline and its active hydroxy metabolite (M1), both of which are substrates of the isoenzyme. In a study consisting of eight healthy, nonsmoking volunteers, mean pentoxifylline systemic exposure (AUC) increased by approximately 35% when pentoxifylline 300 mg was administered intravenously one hour after a single 750 mg oral dose of ciprofloxacin, a moderate CYP450 1A2 inhibitor. The R- and S-enantiomers of the M1 metabolite also increased by 39% and 37%, respectively.

MANAGEMENT: Pharmacologic response to pentoxifylline should be monitored more closely whenever a potent or moderate CYP450 1A2 inhibitor is added to or withdrawn from therapy, and the pentoxifylline dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience serious adverse effects such as bleeding, angina, or arrhythmias.

References

  1. (2001) "Product Information. Trental (pentoxifylline)." Hoechst Marion Roussel
  2. Magnusson M, Bergstrand IC, Bjorkman S, Heijl A, Roth B, Hoglund P (2006) "A placebo-controlled study of retinal blood flow changes by pentoxifylline and metabolites in humans." Br J Clin Pharmacol, 61, p. 138-47

Switch to consumer interaction data

Drug and food interactions

Moderate

fluvoxaMINE food

Applies to: fluvoxamine

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References

  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
View all 4 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer